Trinity Biotech to Enter Cardiac Diagnostics with Novel Guideline-Compliant Point-of-Care System at MEDICA 2013

Trinity Biotech will be showcasing the new Meritas® Troponin I (TnI) point-of-care test (POC) at this year’s MEDICA trade fair in Düsseldorf, Germany, from the 20th to the 23rd November. This landmark Troponin I test is the only high sensitivity, ACC, ESC and AHA guideline-compliant Troponin assay offering true point-of-care capability.

Designed for use with the revolutionary, state-of-the-art Meritas POC Analyzer, the Meritas Troponin I test enables fast, accurate triage and intervention for patients presenting at the emergency department with a possible myocardial infarction (MI), as well as for risk stratification of patients.

Results, which are traceable to NIST SRM 2921, are comparable to those obtained using traditional top performing laboratory analyzers, and are available in just 15 minutes. Turnaround times, patient care and outcomes are improved, helping to maximize the use of precious hospital resources and generate significant cost savings. Studies are currently underway to validate the clinical performance of the Meritas Troponin I POC test to obtain CE marking, and additional assays are being developed to extend the test menu further.